Trial Profile
A Phase 1b, Multicenter, Dose-Escalation Study of LY573636-sodium in Combination With Liposomal Doxorubicin in Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Tasisulam (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 13 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 13 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2012 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.